Mazdutide: China's GLP-1 Weight Loss Drug — What We Know

Mazdutide: China's Entry Into the GLP-1 Weight Loss Race

Mazdutide (IBI362/LY3305677) is a dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics in partnership with Eli Lilly. Approved by China's National Medical Products Administration (NMPA) in early 2025 for weight management, mazdutide represents a significant milestone: it is the first domestically developed GLP-1-based obesity drug approved in China, and its emergence signals that the global GLP-1 market is no longer exclusively a Novo Nordisk and Eli Lilly duopoly. This article is for educational purposes only; consult a qualified physician before considering any medication.

Mazdutide shares the same dual GLP-1/glucagon mechanism as survodutide (Boehringer Ingelheim's competitor), but its development has followed a distinctly Chinese regulatory and commercial pathway. Understanding mazdutide matters for several reasons: it provides competitive clinical data, it could dramatically reshape global pricing dynamics for GLP-1 therapies, and it may become the first GLP-1 obesity drug that is genuinely affordable at scale.

Mechanism of Action

Mazdutide is a once-weekly subcutaneous injectable that simultaneously activates two hormone receptors:

• GLP-1 receptor agonism provides the core weight loss mechanism: appetite suppression, delayed gastric emptying, and improved glycemic control.
• Glucagon receptor agonism adds increased energy expenditure through hepatic fatty acid oxidation and thermogenesis, plus direct liver fat reduction.

The combination allows mazdutide to promote weight loss through both reduced caloric intake and increased caloric expenditure — the same dual-pathway advantage that differentiates glucagon-containing agonists from GLP-1-only drugs like semaglutide. The fatty acid side chain extends the half-life, enabling once-weekly dosing.

GLORY Trial Results

GLORY-1 (Phase 3, China)

The pivotal Phase 3 trial (GLORY-1) enrolled Chinese adults with obesity (BMI 28 or above) or overweight (BMI 24 or above) with at least one weight-related comorbidity^[1]:

Treatment	Weight Loss at 48 Weeks	Subjects Achieving 5% or more	Subjects Achieving 10% or more
Placebo	-3.2%	22%	8%
Mazdutide 6 mg	-14.4%	80%	58%
Mazdutide 9 mg	-16.6%	87%	68%

The 9 mg dose produced 16.6% body weight loss at 48 weeks, with 46% of participants achieving 20% or greater weight loss. These results are competitive with semaglutide (Wegovy, ~15%) and position mazdutide as a strong contender.

GLORY-2 (Type 2 Diabetes)

In the Phase 3 GLORY-2 trial for type 2 diabetes, mazdutide demonstrated:

• HbA1c reduction: -1.5 to -1.6 percentage points from baseline
• Weight loss: -7.1% to -8.6% (in a diabetes population)
• Fasting glucose improvement: Significant reductions across doses

An important caveat: the GLORY trials were conducted in Chinese populations, where BMI thresholds for obesity are lower and metabolic responses may differ. Cross-ethnic comparisons require careful interpretation.

Why Mazdutide Matters Globally

China's Obesity Epidemic

China has the world's largest population of obese and overweight individuals — an estimated 300+ million people with obesity and 500+ million who are overweight. Until mazdutide's approval, China relied primarily on imported GLP-1 drugs facing supply constraints and high costs^[2].

Pricing and Market Implications

Mazdutide's most disruptive potential lies in pricing. In China, the monthly cost is expected to be a fraction of what semaglutide and tirzepatide command in Western markets:

• Domestic manufacturing. Innovent produces mazdutide in China, avoiding supply chain constraints and premium pricing of imported biologics.
• Chinese pricing dynamics. China's National Reimbursement Drug List (NRDL) negotiations typically drive dramatic price reductions. If mazdutide enters the NRDL, its price could drop by 40-70% from the initial list price.
• Market scale. The scale of demand enables lower per-unit pricing.
• Competitive pressure. Multiple Chinese pharmaceutical companies are developing GLP-1 agonists, creating domestic competition that will drive prices lower.

The Chinese GLP-1 Market

Drug	Company	China Status	Mechanism
Semaglutide (Wegovy)	Novo Nordisk	Approved (imported)	GLP-1
Tirzepatide (Mounjaro)	Eli Lilly	Approved	GLP-1/GIP
Mazdutide (Maiyoule)	Innovent/Lilly	Approved (domestic)	GLP-1/Glucagon
Orforglipron	Eli Lilly	Phase III	Oral GLP-1

Dual Agonism: GLP-1/Glucagon vs GLP-1/GIP

The GLP-1/glucagon pairing (mazdutide, survodutide) represents a different strategic bet than the GLP-1/GIP pairing (tirzepatide):

Aspect	GLP-1/Glucagon (Mazdutide)	GLP-1/GIP (Tirzepatide)
Energy Expenditure	Increased (glucagon-driven)	Minimal direct effect
Liver Fat Reduction	Potentially superior (glucagon)	Good (weight-loss driven)
Weight Loss	~16-17%	~22.5%
Glycemic Control	Strong	Strong
Muscle Preservation	May be better (thermogenesis)	Less studied

Side Effects

Mazdutide's side effect profile in the GLORY trials was consistent with other GLP-1-class drugs:

• Nausea: 28-38% (most common; decreases after initial weeks)
• Diarrhea: 14-19%
• Vomiting: 10-17%
• Decreased appetite: 10-15%
• Injection site reactions: 5-8%
• Constipation: 5-10%

Discontinuation rates due to adverse events were approximately 5-8%, comparable to or lower than rates seen with semaglutide. For a broader view of side effect profiles, see our complete side effects guide.

Dosing Protocol

Mazdutide uses a once-weekly subcutaneous injection with the following titration schedule:

• Weeks 1-4: 1.5 mg weekly
• Weeks 5-8: 3.0 mg weekly
• Weeks 9-12: 4.5 mg weekly
• Weeks 13+ (optional escalation): 6.0 mg weekly
• Weeks 17+ (optional further escalation): 9.0 mg weekly

Dose escalation is guided by tolerability. Many patients achieve clinically meaningful weight loss at the 4.5-6.0 mg dose without needing to escalate to 9.0 mg.

Global Development Outlook

While mazdutide is approved in China, its path to other markets is evolving:

• United States: Eli Lilly holds ex-China rights but has not announced US Phase III plans, likely prioritizing tirzepatide and retatrutide
• Rest of world: Development outside China remains uncertain
• Potential niche: Mazdutide could find a role as a MASH-focused therapy globally, given the glucagon component's hepatic benefits

Implications for the Peptide Community

Mazdutide's approval has several implications for the broader weight loss landscape:

• Dual-agonist validation: The approval validates the GLP-1/glucagon approach, supporting the rationale for similar compounds like survodutide
• Market competition: More competition could drive down prices globally, improving accessibility
• Peptide alternatives: Research peptides like AOD-9604, tesamorelin, and GH-releasing peptides like CJC-1295/ipamorelin continue to serve individuals seeking non-GLP-1 approaches to body composition

For a comprehensive comparison of approaches, see our weight-loss peptides goal page and AOD-9604 vs semaglutide analysis.

The Bottom Line

Mazdutide is a competitive GLP-1/glucagon dual agonist that has proven its efficacy in a large Chinese clinical program and achieved NMPA approval for weight management. Its clinical results are in the same ballpark as Western competitors, and its potential pricing advantage could be transformative for global GLP-1 accessibility. Whether it reaches Western markets depends on Eli Lilly's strategic decisions, but its impact on global pricing dynamics and competitive pressure is already being felt. For anyone tracking the evolution of GLP-1 weight loss therapies, mazdutide represents an important data point showing that effective dual-agonist therapy can be developed, approved, and potentially priced for mass-market accessibility.